A Study to Test How Well Different Doses of BI 1356225 Are Tolerated by Men and Women With Obesity or Overweight
Status:
Completed
Trial end date:
2021-04-25
Target enrollment:
Participant gender:
Summary
The primary objective of this trial is to investigate safety and tolerability of BI 1356225
in male and female patients with overweight and obesity following oral administration of
multiple rising doses per day over 28 days. Secondary objectives are the exploration of
pharmacokinetics (PK) of BI 1356225 after multiple oral dosing. Additionally, the relative
bioavailability (BA) of midazolam and celecoxib in the presence and absence of BI 1356225
will be evaluated